Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been assigned a consensus rating of “Moderate Buy” from the eighteen brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, twelve have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $37.8125.

A number of analysts have recently issued reports on DYN shares. Royal Bank Of Canada lifted their price target on Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. lowered their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. Morgan Stanley boosted their price target on shares of Dyne Therapeutics from $46.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Evercore decreased their price target on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, December 15th. Finally, Sanford C. Bernstein set a $23.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, December 9th.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Darwin Wealth Management LLC increased its position in shares of Dyne Therapeutics by 0.5% during the 3rd quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock valued at $2,195,000 after purchasing an additional 861 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after buying an additional 955 shares during the last quarter. Creative Planning boosted its stake in Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after buying an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after acquiring an additional 1,109 shares during the last quarter. Finally, Caxton Associates LLP raised its stake in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after acquiring an additional 1,627 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Down 3.5%

DYN opened at $15.62 on Friday. The firm has a market capitalization of $2.23 billion, a P/E ratio of -4.27 and a beta of 1.30. Dyne Therapeutics has a one year low of $6.36 and a one year high of $25.00. The company has a fifty day moving average price of $17.57 and a 200-day moving average price of $16.94. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.